Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275254 | 0.80 | KDR (0.49) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL16774914 | 0.80 | PTK2 (0.54) | KDREGFRWDR5KMT2AFGFR1 | |
| SCHEMBL4491507 | 0.77 | EGFR (0.47) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL1094439 | 0.75 | EGFR (0.49) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL29544568 | 0.74 | WDR5 (0.74) | WDR5KMT2A | |
| SCHEMBL6237775 | 0.74 | EGFR (0.61) | EGFR | |
| SCHEMBL4921796 | 0.74 | EGFR (0.51) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL689999 | 0.72 | EGFR (0.46) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL27830021 | 0.72 | EGFR (0.65) | KDREGFRRETKIF5BDYRK1A | |
| SCHEMBL26245874 | 0.72 | WDR5 (0.53) | WDR5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2005009384-A2 | EGFR TYROSINE KINASE INHIBITORS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDR 4576/4885EGFR 4695/4885RET 3586/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDR 4576/4885EGFR 4695/4885RET 3586/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | KDR 4576/4885EGFR 4695/4885RET 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.